v3.25.2
Segment Information - Summary of Selected Financial Information with Respect to Single Operating Segment (Detail) - USD ($)
$ in Thousands
3 Months Ended
Jul. 31, 2025
Jul. 31, 2024
Segment Reporting Information [Line Items]    
Product revenue, net $ 1,426  
Operating expenses:    
Cost of revenue 590  
Clinical development 7,791 $ 14,449
Research 10,329 10,560
Regulatory & QA 2,196 1,605
Pre-commercial planning 27,088 10,651
Other SG&A 12,441 6,950
Total operating expenses 60,435 44,215
Operating loss (59,009) (44,215)
Interest and other income (expense), net 1,070 3,772
Loss before income taxes (57,939) (40,443)
Provision for (benefit from) for income taxes 2,157 0
Net loss $ (60,096) $ (40,443)